Mint Venture Partners

Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on the development of anti-cancer drugs utilizing a proprietary proteolysis targeting chimera platform. The company employs advanced inhibitor technology that degrades specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with disease, Ubix Therapeutics seeks to provide life-saving medications for patients, thereby supporting both patients and medical professionals in the fight against cancer.

The company is a spin-off from Asan Medical Center, University of Ulsan University, with a primary objective of developing therapeutic and diagnostic agents for neurological diseases, particularly Alzheimer's disease. In 2016, the company took significant steps toward formalizing its presence in the market by completing its incorporation and business registration processes. The year 2017 proved to be a milestone for the company as it obtained certification as a corporate-affiliated research institute, solidifying its position as a reputable research-driven organization. Additionally, it garnered recognition as a leading university start-up by the Ministry of SMEs and Startups, further boosting its credibility and potential for growth. The company has collaborated with Oscotech Co., Ltd. and partnered with various investors, including Kite Entrepreneurship Foundation, Stone Bridge Ventures Co., Ltd., Korea Development Bank, and Stick Ventures Co., Ltd., to jointly develop their projects.

Medinno Inc., established in 2016 and headquartered in Suwon, South Korea, specializes in the research and development of neural stem cell therapies derived from adult brain tissue. The company focuses on creating therapeutic agents for treating a wide array of degenerative neurological diseases, including hypoxic-ischemic encephalopathy, neonatal refractory brain diseases, severe intraventricular hemorrhages, stroke, and Alzheimer's disease. Medinno aims to enable physicians to effectively address these conditions through its innovative cell therapeutics.

Aimedbio is a healthcare company focused on delivering therapeutic solutions for patients suffering from serious brain diseases. The company specializes in developing therapeutic systems and medications aimed at treating neuro-oncological and degenerative conditions. Aimedbio's mission is to enhance the quality of life for individuals dealing with refractory brain diseases, including various forms of cancer. Through its innovative approaches, the company seeks to address significant unmet medical needs in the field of neurology.

Humanscape, Inc. is a health-tech company based in Seoul, South Korea, founded in 2016. It specializes in developing blockchain software to collect and process health information from patients with rare and intractable diseases. By compiling comprehensive health data, including genotype, clinical, and phenotype information, Humanscape creates ready-to-use data sets that facilitate drug development. This systematic approach enables pharmaceutical companies and researchers to significantly reduce both the time and cost associated with developing new treatments. Through its innovative platform, Humanscape aims to improve the chances of cures for patients suffering from rare diseases, ultimately enhancing medical practices and treatment outcomes.

SanaHeal is a company focused on developing innovative bioadhesive materials, specifically designed to enhance surgical outcomes. It offers a range of products, including bioadhesive tapes, pastes, and powders, which can effectively bind tissues or organs, serving as alternatives to traditional sutures. These products aim to promote healing while minimizing complications following surgical procedures. SanaHeal's technology is particularly beneficial for patients with multiple traumatic injuries, facilitating improved integration of medical devices with the human body and providing essential care during recovery. Through its advancements in bioadhesive solutions, the company seeks to transform the management of wounds and bleeding in surgical settings.

Activ Surgical Inc. is a digital surgery company based in Boston, Massachusetts, dedicated to enhancing surgical procedures through advanced technology. Established in 2014 and originally known as Omniboros Inc., the company specializes in developing a robotic surgery platform that integrates computer vision, artificial intelligence, and robotics. Its flagship product, the Smart Tissue Autonomous Robot (STAR), is designed to improve surgical efficiency, accuracy, and patient outcomes while reducing the risk of unintended complications. Activ Surgical's innovative, patent-protected surgical software facilitates augmented reality-based and AI-driven operations, thereby enhancing surgeons' intra-operative decision-making and fostering safer surgical practices.

BeauBrain Healthcare is dedicated to transforming the management of Alzheimer's Disease and related dementias by focusing on pre-emptive interventions rather than post-diagnosis treatments. The company has developed a diagnostic platform that integrates cognitive tests and brain imaging scans to assess brain activity and structure. This innovative approach enables the early identification of risk factors associated with dementia by analyzing disease-specific biomarkers, including Amyloid Beta and Tau. By detecting subtle changes in brain function years before symptoms manifest, BeauBrain Healthcare empowers individuals and healthcare professionals to implement proactive measures such as personalized cognitive training programs and lifestyle modifications. The company aims to advance precision medicine for Alzheimer's Disease by combining biomarker data with extensive genetic information, ultimately addressing the growing challenge posed by neurodegenerative diseases in an aging population.

SeaWith is a biotechnology startup focused on creating cell-cultured steak derived from seaweed, specifically utilizing a low-iodine seaweed variant known as Yo.od. The company aims to provide a sustainable alternative to traditional meat production by developing clean meat in a laboratory setting. SeaWith employs its proprietary culture media, made from microalgae, to cultivate meat that retains the taste and texture of conventional meat while being more affordable due to the abundance of microalgae. By doing so, SeaWith addresses the ethical and environmental challenges associated with livestock farming, offering consumers a delicious and cost-effective protein source that aligns with growing demands for sustainable food options.

Organoid Sciences is a biotechnology company founded in 2018 and located in Seongnam-si, South Korea. The company specializes in developing organoid-based therapies using its proprietary Keo cannabinoid technology to address various incurable diseases. In addition to drug development, Organoid Sciences provides drug screening services and focuses on regenerative medicine, aiming to advance treatment options through innovative approaches.

Sonic Incytes Medical Corp is a medical device company based in Vancouver, Canada, focused on developing handheld ultrasound solutions for the assessment and monitoring of chronic liver diseases. Incorporated in 2012, the company specializes in quantitative ultrasound technology that supports point-of-care diagnostics and procedure guidance. Its portable devices provide a non-invasive method for diagnosing liver diseases, particularly in quantifying fatty liver disease, thereby enhancing the standard of care provided by medical practitioners. The company's mission is to facilitate routine assessment and management of liver health with reliable diagnostic accuracy.

Key Proteo is a biotechnology company focused on advancing newborn screening programs through innovative peptide screening technology. The company specializes in multiplex analysis of extremely low-abundance proteins extracted from a few drops of blood, using surrogate peptide markers analyzed by mass spectrometry. By enhancing existing screening methods, Key Proteo aims to identify genetic diseases in newborns before they manifest clinically, allowing for timely interventions that can alter the course of these conditions. This approach not only targets both new and known genetic disorders but also strives to improve the overall quality of life for affected infants and their families.

GenoTwin is a company dedicated to integrating genomics into public health to tackle infectious disease challenges. It offers an innovative genomics platform that leverages advanced technologies in genomics, artificial intelligence, and computational biology. The platform supports clinicians, public health officials, and researchers in four primary areas: pathogen detection, pathogen surveillance, immune and resistance assessment, and precision treatment. By employing genome big data analysis, GenoTwin enables early identification and control of emerging pathogens, ultimately aiming to reduce mortality rates, enhance yield in livestock operations, and improve the effectiveness of targeted treatments in both infectious diseases and cancer.

Charco Neurotech is a medical technology company focused on creating non-invasive wearable devices aimed at enhancing the quality of life for individuals with Parkinson's disease. The company's primary innovation involves a wearable device that modulates sensory dysfunction, which aids users in improving their movement speed and overall mobility. By addressing specific challenges faced by those living with Parkinson's, Charco Neurotech seeks to empower individuals to maintain a more active and normal lifestyle.

Activ Surgical Inc. is a digital surgery company based in Boston, Massachusetts, dedicated to enhancing surgical procedures through advanced technology. Established in 2014 and originally known as Omniboros Inc., the company specializes in developing a robotic surgery platform that integrates computer vision, artificial intelligence, and robotics. Its flagship product, the Smart Tissue Autonomous Robot (STAR), is designed to improve surgical efficiency, accuracy, and patient outcomes while reducing the risk of unintended complications. Activ Surgical's innovative, patent-protected surgical software facilitates augmented reality-based and AI-driven operations, thereby enhancing surgeons' intra-operative decision-making and fostering safer surgical practices.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Mezoo is a medical device manufacturing company focused on developing innovative biomedical sensor technology aimed at enhancing human health through accurate diagnoses. The company specializes in creating a small, patch-type electrocardiogram that adheres to the chest of the test subject. This device enables real-time monitoring of cardiac activity, allowing physicians to effectively manage and prevent heart disease in patients. Through its advanced technology, Mezoo contributes to improving health outcomes and advancing the field of medical diagnostics.

NEXTON is an indoor vertical farming company based in Seoul, South Korea, established in 2017. The company specializes in the cultivation of agricultural products, focusing on hydroponically grown vegetables and herbs, including leafy greens and Korean strawberries. NEXTON operates its farm under conditions that maintain natural temperatures between 10-20°C year-round, utilizing photosynthetically-active LED lighting and a fully-recycled, chemical-free nutrient water system. This sustainable approach allows NEXTON to produce its crops without the use of pesticides or herbicides. In addition to vegetables, the company also cultivates pharmaceutical plants and ingredients for cosmetics, emphasizing a commitment to innovative and environmentally friendly agricultural practices.

Hyperfine is a pioneering medical device company known for developing Swoop, the first FDA-cleared point-of-care MRI system. Swoop is designed to enhance patient access to rapid diagnosis and treatment, regardless of socioeconomic factors or geographic location. This innovative portable MRI system operates at a lower magnetic field strength than traditional MRI machines, allowing for high-quality imaging in a variety of clinical environments. Swoop can be easily transported to a patient's bedside, requires only a standard electrical outlet, and is controlled via an iPad, facilitating quick scans that support critical decision-making in settings such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of its MRI devices as well as service sales, which include subscriptions for bundled devices, maintenance, and software.